$591 Million is the total value of Bain Capital Life Sciences Investors, LLC's 11 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 50.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ARQT | New | ARCUTIS BIOTHERAPEUTICS, INC. | $118,583,000 | – | 3,979,292 | +100.0% | 20.06% | – |
DVAX | Buy | DYNAVAX TECHNOLOGIES CORP. | $30,819,000 | -36.3% | 8,730,707 | +3.3% | 5.21% | -27.7% |
APTX | Buy | APTINYX INC | $12,006,000 | +57.8% | 5,558,425 | +149.8% | 2.03% | +78.9% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, LP #2
- BC SW, LP #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
APTINYX INC | 20 | Q1 2023 | 16.9% |
SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
SAVARA INC | 16 | Q3 2023 | 6.0% |
X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
4 | 2024-02-14 |
13F-HR | 2024-02-13 |
3 | 2024-02-07 |
4 | 2024-01-12 |
3 | 2023-12-29 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
3 | 2023-05-30 |
4 | 2023-05-30 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.